Literature DB >> 7693457

Uridylate-containing RNA sequences determine specificity for binding and polyadenylation by the catalytic subunit of vaccinia virus poly(A) polymerase.

P D Gershon1, B Moss.   

Abstract

VP55, the catalytic subunit of vaccinia virus poly(A) polymerase, has the remarkable property of adding 30-35 adenylates to RNA 3' ends in a rapid processive burst before an abrupt transition to slow, non-processive adenylate addition. Here, we demonstrate that this property results from the affinity of the enzyme for uridylate residues within the 3' 31-40 nt of the RNA primer. At physiological salt concentrations, both polyadenylation and stable VP55 binding required the presence of multiple uridylates within a 31-40 nt length of RNA, though specific RNA sequences were not necessary. Even DNA in which the deoxythymidylate residues were replaced with ribouridylates, could be polyadenylated in a processive manner. Both the unmethylated pyrimidine ring and a 2'-OH on the associated sugar are features of ribouridylates that are important for priming. The abrupt termination of processive polyadenylation was attributed to translocation of VP55 along the nascent poly(A) tail, which lacks uridylates for stable binding. As evidence for translocation and interaction with newly synthesized RNA, other homopolymer tails were synthesized by VP55 in the presence of Mn2+, which relaxes its donor nucleotide specificity. Only during poly(U) tail synthesis did processive nucleotide addition fail to terminate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693457      PMCID: PMC413915          DOI: 10.1002/j.1460-2075.1993.tb06159.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  24 in total

1.  Transition from rapid processive to slow nonprocessive polyadenylation by vaccinia virus poly(A) polymerase catalytic subunit is regulated by the net length of the poly(A) tail.

Authors:  P D Gershon; B Moss
Journal:  Genes Dev       Date:  1992-08       Impact factor: 11.361

2.  Cloning and domain structure of the mammalian splicing factor U2AF.

Authors:  P D Zamore; J G Patton; M R Green
Journal:  Nature       Date:  1992-02-13       Impact factor: 49.962

3.  Poly(A) polymerase and a dissociable polyadenylation stimulatory factor encoded by vaccinia virus.

Authors:  P D Gershon; B Y Ahn; M Garfield; B Moss
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

4.  Characterization and molecular cloning of polypyrimidine tract-binding protein: a component of a complex necessary for pre-mRNA splicing.

Authors:  J G Patton; S A Mayer; P Tempst; B Nadal-Ginard
Journal:  Genes Dev       Date:  1991-07       Impact factor: 11.361

Review 5.  Cytoplasmic transcription system encoded by vaccinia virus.

Authors:  B Moss; B Y Ahn; B Amegadzie; P D Gershon; J G Keck
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

Review 6.  RNA-binding proteins as developmental regulators.

Authors:  R J Bandziulis; M S Swanson; G Dreyfuss
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

7.  A common RNA recognition motif identified within a defined U1 RNA binding domain of the 70K U1 snRNP protein.

Authors:  C C Query; R C Bentley; J D Keene
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

8.  Characterization of cDNAs encoding the polypyrimidine tract-binding protein.

Authors:  A Gil; P A Sharp; S F Jamison; M A Garcia-Blanco
Journal:  Genes Dev       Date:  1991-07       Impact factor: 11.361

9.  Cap-specific mRNA (nucleoside-O2'-)-methyltransferase and poly(A) polymerase stimulatory activities of vaccinia virus are mediated by a single protein.

Authors:  B S Schnierle; P D Gershon; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

10.  The human 64-kDa polyadenylylation factor contains a ribonucleoprotein-type RNA binding domain and unusual auxiliary motifs.

Authors:  Y Takagaki; C C MacDonald; T Shenk; J L Manley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  8 in total

1.  Interplay of two uridylate-specific RNA binding sites in the translocation of poly(A) polymerase from vaccinia virus.

Authors:  L Deng; P D Gershon
Journal:  EMBO J       Date:  1997-03-03       Impact factor: 11.598

2.  Pervasive initiation and 3'-end formation of poxvirus postreplicative RNAs.

Authors:  Zhilong Yang; Craig A Martens; Daniel P Bruno; Stephen F Porcella; Bernard Moss
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

3.  Ordered assembly of a functional preinitiation transcription complex, containing vaccinia virus early transcription factor and RNA polymerase, on an immobilized template.

Authors:  C J Baldick; M C Cassetti; N Harris; B Moss
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

4.  Characterization of small nontranslated polyadenylylated RNAs in vaccinia virus-infected cells.

Authors:  C Lu; R Bablanian
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

5.  The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription.

Authors:  R W Hardy; G W Wertz
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  The myxoma virus EcoRI-O fragment encodes the DNA binding core protein and the major envelope protein of extracellular poxvirus.

Authors:  R J Jackson; D F Hall
Journal:  Virus Genes       Date:  1998       Impact factor: 2.198

7.  mRNA maturation in giant viruses: variation on a theme.

Authors:  Stéphane Priet; Audrey Lartigue; Françoise Debart; Jean-Michel Claverie; Chantal Abergel
Journal:  Nucleic Acids Res       Date:  2015-03-16       Impact factor: 16.971

8.  Quantitative Analysis of MicroRNAs in Vaccinia virus Infection Reveals Diversity in Their Susceptibility to Modification and Suppression.

Authors:  Amy H Buck; Alasdair Ivens; Katrina Gordon; Nicola Craig; Alexandre Houzelle; Alice Roche; Neil Turnbull; Philippa M Beard
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.